China Medical System Hldgs 

China Medical System Holdings Limited functions as an investment holding enterprise, primarily focused on the development, manufacturing, commercialization, and distribution of pharmaceutical products throughout the People's Republic of China. The company offers an extensive range of treatments across several therapeutic areas. Its cardio-cerebrovascular portfolio includes VELPHORO, comprising sucroferric oxyhydroxide chewable tablets and a diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide formulated for acute heart failure; Plendil, felodipine sustained-release tablets designed to manage hypertension; and Deanxit, a combination of flupentixol and melitracen tablets targeting mild-to-moderate depression. Within its gastroenterology segment, products feature METOJECT, a methotrexate injection indicated for severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, methylthioninium chloride enteric-coated sustained-release tablets used for visualizing colorectal lesions; Salofalk, applied in the treatment of ulcerative colitis and Crohn's disease; Bioflor, saccharomyces boulardii sachets addressing diarrhea; the digestive enzymes Combizym and Cidine; and Ursofalk, ursodeoxycholic acid capsules for dissolving cholesterol gallstones. The dermatology division includes ILUMETRI, a tildrakizumab injection for treating plaque psoriasis; Aethoxysklerol, a polidocanol injection employed in the sclerotherapy of various varicose veins; and Hirudoid, a mucopolysaccharide polysulfate cream utilized for blunt traumata, skin healing, soothing, and acne-prone skin care and prevention. Additionally, the company provides a range of specialized products such as Vmonalisa, a modified sodium hyaluronate filler for mid to deep dermal implantation; augentropfen stulln mono eye drops for asthenopia; the EyeOP1 device for glaucoma treatment; and Elcitonin, prescribed for osteoporosis pain. Established in 1995, China Medical System Holdings Limited maintains its corporate headquarters in North Point, Hong Kong, and operates as a subsidiary of Treasure Sea Limited.